Clinical Trials on Hormone Receptor-positive Breast Cancer

Total 18285 results

Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Ductal Carcinoma in Situ

United States
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
Hoffmann-La Roche

Terminated

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy (Veronica)

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Canada, United States, United Kingdom, Australia, Germany
Stemline Therapeutics, Inc.

Completed

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

United States
Virginia Polytechnic Institute and State University
Carilion Clinic

Completed

Prospective Thinking in Hormone-Responsive Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Hormone Receptor Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States, Puerto Rico, Ireland
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
University of Pennsylvania

Active, not recruiting

FDG PET/CT in Breast Cancer Bone Mets

Bone Metastases | Estrogen Receptor Positive Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Seoul National University Hospital

Completed

Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

Korea, Republic of
Organisation for Oncology and Translational Research

Unknown

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

China
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
Institut Curie

Unknown

Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

Ductal Infiltrating Metastatic Breast Cancer | Hormone-receptors Positive Breast Cancer

France
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Hormone Receptor Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Terminated

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Node-negative Breast Cancer

United States
Jules Bordet Institute
KU Leuven; University of Milan

Not yet recruiting

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) (KePreSt)

Early-stage Breast Cancer | Estrogen-receptor-positive Breast Cancer

Belgium
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Gustave Roussy, Cancer Campus, Grand Paris
European Commission

Completed

Identification of Early Markers of Response and Resistance to Trastuzumab (HERBIN)

Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer

France
Rush University Medical Center

Completed

Patterns of Prescribing and Monitoring of Palbociclib

Advanced Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
National Cancer Institute (NCI)

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
Incyclix Bio

Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)

Breast Cancer | Ovarian Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Breast Cancer Metastatic | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | CCNE1 Amplification

United States, Australia
Mayo Clinic

Not yet recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Breast Adenocarcinoma | Estrogen Receptor-Positive Breast Carcinoma | Progesterone Receptor-Positive Breast Carcinoma

United States
Azienda Ospedaliero-Universitaria Careggi

Completed

Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) (AIA)

Breast Cancer | Arthralgia | Hormone Receptor Positive Tumor

Italy
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Estrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA Gene

United States, Netherlands, Spain, Germany, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Centro di Riferimento Oncologico - Aviano

Recruiting

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (MAGNETIC1)

Breast Neoplasms | Breast Diseases | Antineoplastic Agents | Aromatase Inhibitors | Neoplasms, Breast | Hormone Receptor Positive Breast Carcinoma | ESR1 Gene Mutation

Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Mobile Health for Adherence in Breast Cancer Patients

Breast Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditions

United States
Rutgers, The State University of New Jersey
Rutgers Cancer Institute of New Jersey; Elekta Limited; Cianna Medical, Inc.

Completed

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery (TRIUMPH-T)

Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ

United States
Vanderbilt-Ingram Cancer Center
Genentech, Inc.; Stand Up To Cancer

Terminated

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | Estrogen Receptor-positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors

Cancer Survivor | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Postmenopausal

United States
University of Washington
National Cancer Institute (NCI)

Terminated

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Recurrent Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
Aarhus University Hospital
Danish Cancer Society

Recruiting

The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity (FEMA)

Metastatic Breast Cancer | Adiposity | Estrogen-receptor-positive Breast Cancer

Denmark
Novartis Pharmaceuticals

Terminated

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

Germany
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Cianna Medical, Inc.

Terminated

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Hormone Receptor-Positive Breast | Gynecologic | Desmoid | Hormone Receptor-Positive Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative

United States
Gangnam Severance Hospital
Samsung Medical Center; Asan Medical Center; Severance Hospital

Recruiting

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR)

Breast Cancer | Surgery | Recurrent Breast Cancer | Estrogen Receptor Positive Tumor | Stereotactic Body Radiotherapy | Her2-negative Tumor

Korea, Republic of
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
National Cancer Institute (NCI)
National Institutes of Health (NIH)

Completed

Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States

Clinical Trials on Hormone Receptor-positive Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations